Pharmaceutical giant, Pfizer, announced on Monday that its coronavirus vaccine trial has proven effective in preventing Covid-19 infections in 90% of previously uninfected people and did not produce any serious safety concerns.
This would be a huge breakthrough in the fight against the coronavirus pandemic, if the results bear out.
Pfizer, which developed the vaccine with German pharmaceutical company, BioNTech, says it will seek emergency authorization from America’s FDA by the end of the month.
The firm says that it had enrolled “43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of Nov. 8, 2020.
“The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued,” according to Axios reports.
The company “released only sparse details” from the trial, and scientists “have cautioned against hyping early results before long-term safety and efficacy data has been collected”, it added.
